← Leaderboards
Savio L Woo
Mount Sinai School Of Medicine Of Nyu
$12,415,247
Attributed
$12,415,247
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–11$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$12,415,247 · 12
By mechanism
R01$9,408,713 · 6
R24$1,271,025 · 1
R21$858,851 · 2
U54$590,456 · 1
P20$239,702 · 1
R13$46,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Gordon M Keller$15,763,721
- Reigh-Yi Lin$2,915,093
- Ralph Michael Linden$5,325,404
Others in their field
Top investigators on “Virus Replication”
- Constance Ann Benson · University Of California, San Diego$187,673,896
- Judith S. Currier · University Of California Los Angeles$137,892,773
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Barton F Haynes · Duke University$110,672,613
- Charles M. Rice · Rockefeller University$53,754,576
- Rama Rao Amara · Emory University$53,347,944
Research focus
Virus ReplicationGene TherapyVirusLiverLeadToxic EffectTransfection /Expression VectorFutureAnimalsLesionDoseTumorMalignant NeoplasmsCellsImmuneRecombinantsCessation Of LifeGene ExpressionCancer TherapySafetyCancer EtiologyAttenuatedGenetic Regulatory ElementNeoplastic Cell
Grant awards (42)
Oncolytic VSV for Hepatocellular Carcinoma$327,933
R01 · FY2011 · CA · contact PI
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC$488,385
R01 · FY2010 · CA · contact PI
Oncolytic VSV for Hepatocellular Carcinoma$338,076
R01 · FY2010 · CA · contact PI
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC$487,236
R01 · FY2009 · CA · contact PI
Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer$351,713
R01 · FY2009 · CA · contact PI
Oncolytic VSV for Hepatocellular Carcinoma$338,076
R01 · FY2009 · CA · contact PI
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC$595,625
R01 · FY2008 · CA · contact PI
Oncolytic VSV for Hepatocellular Carcinoma$338,076
R01 · FY2008 · CA · contact PI
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC$592,173
R01 · FY2007 · CA · contact PI
Oncolytic VSV for Hepatocellular Carcinoma$338,076
R01 · FY2007 · CA · contact PI
Anaerobic Bacteria as Therapeutic Agents for Metastatic Cancer$187,626
R21 · FY2007 · CA · contact PI
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS$128,536
P20 · FY2007 · GM · contact PI
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC$594,231
R01 · FY2006 · CA · contact PI
Onoclytic VSV for Hepatocellular Carcinoma$331,447
R01 · FY2006 · CA · contact PI
Genetic Reconstitution for Phenylketonuria$309,322
R01 · FY2006 · DK · contact PI
Vector Core Production Facility at Mount Sinai$263,581
R24 · FY2006 · CA · contact PI
Anaerobic Bacteria as Therapeutic Agents for Metastatic$161,025
R21 · FY2006 · CA · contact PI
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS$55,583
P20 · FY2006 · GM · contact PI
Onoclytic VSV for Hepatocellular Carcinoma$339,424
R01 · FY2005 · CA
Genetic Reconstitution for Phenylketonuria$316,766
R01 · FY2005 · DK
Vector Core Production Facility at Mount Sinai$262,547
R24 · FY2005 · CA
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS$55,583
P20 · FY2005 · GM
Onoclytic VSV for Hepatocellular Carcinoma$339,424
R01 · FY2004 · CA
Suppression of Hepatic Gluconeogenesis in IDDM$339,000
R01 · FY2004 · DK
Genetic Reconstitution for Phenylketonuria$316,766
R01 · FY2004 · DK
Vector Core Production Facility at Mount Sinai$255,389
R24 · FY2004 · CA
Genetic Reconstitution for Phenylketonuria$384,989
R01 · FY2003 · DK
Oncolytic VSV for Hepatocellular Carcinoma$339,424
R01 · FY2003 · CA
Suppression of Hepatic Gluconeogenesis in IDDM$339,000
R01 · FY2003 · DK
Interleukin 12 Gene Therapy For Colorectal Cancer$281,375
R21 · FY2003 · CA
Vector Core Production Facility at Mount Sinai$248,372
R24 · FY2003 · CA
Suppression of Hepatic Gluconeogenesis in IDDM$339,000
R01 · FY2002 · DK
Vector Core Production Facility at Mount Sinai$241,136
R24 · FY2002 · CA
CORE--MOLECULAR BIOLOGY$174,159
U54 · FY2002 · HD
CORE--MOLECULAR BIOLOGY$174,159
U54 · FY2002 · HD
Suppression of Hepatic Gluconeogenesis in IDDM$339,000
R01 · FY2001 · DK
HEPATIC INSULIN GENE EXPRESSION IN IDDM$297,101
R01 · FY2001 · DK
Interleukin 12 Gene Therapy For Colorectal Cancer$228,825
R21 · FY2001 · CA
CORE--MOLECULAR BIOLOGY$174,159
U54 · FY2001 · HD
HEPATIC INSULIN GENE EXPRESSION IN IDDM$288,450
R01 · FY2000 · DK
CORE--MOLECULAR BIOLOGY$67,979
U54 · FY2000 · HD
ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE THERAPY$46,500
R13 · FY2000 · CA